Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 9Lymphoma, Non-Hodgkin 7Recurrence 2Lymphoma 2Cytokine Release Syndrome 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Glioblastoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1Astrocytoma 1Advanced Liver Cancers 1

Interventions

venetoclax 28Rituximab 22ibrutinib 21acalabrutinib 21Cyclophosphamide 20Specimen Handling 18obinutuzumab 15Biopsy 14fludarabine 13zanubrutinib 10pirtobrutinib 10fludarabine phosphate 9Magnetic Resonance Spectroscopy 8Bendamustine Hydrochloride 8idelalisib 6Whole-Body Irradiation 6Mycophenolic Acid 6Lenalidomide 6CT-P10 6ARQ531 6Cyclosporine 5Sirolimus 4Peripheral Blood Stem Cell Transplantation 4pembrolizumab 3Vincristine 3Tacrolimus 3Prednisone 3Doxorubicin 3Disulfides 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × tocilizumab × 90 days × Clear all
NCT05091424 2026-06-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Hoffmann-La Roche

Phase 1 Recruiting
137 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡